Knowledge HQ

This study correlates NK cell receptor repertoires with SARS-CoV-2 clearance. G-Rex 24-well culture plates were used to expand primary NK cells with K562 feeder cells to obtain sufficient cell numbers for functional killing assays.

This study developed mutated GM-CSF-based CAR-T cells targeting CD116/CD131 for AML. The CAR-T cells showed enhanced anti-tumor effects. G-Rex usage was not explicitly mentioned in the provided text.

This study evaluates anti-SIV CAR-T cells in rhesus macaques. Host antibodies inhibited CAR-T expansion in vivo. G-Rex were used during manufacturing to pool and expand CD4+ and CD8+ CAR-T cells prior to infusion into the animals.

This study shows the feasibility of expanding SARS-CoV-2 VSTs from convalescent donors. CD14 negative fractions were seeded in a G-Rex system for a 21-day expansion protocol involving peptide-loaded DCs and PHA blasts, yielding specific T cell products.

This study develops CS1 and bispecific CS1-BCMA CAR-T cells. Bispecific CAR-T cells were effectively expanded over 180-fold in a 1 L G-Rex system, maintaining a central memory phenotype and demonstrating high specific cytotoxicity against multiple myeloma cells.

This paper describes base-edited, fratricide-resistant CAR-T cells targeting CD3 and CD7. Transduced cells were cultured and expanded in G-Rex 24 well, G-Rex 10, or G-Rex 100 chambers. The cells exhibited potent cytotoxicity against T-cell leukemias in vivo.

This study presents an improved TIL production process. Using G-Rex vessels and TIL stimulators, production time was reduced to 3 weeks. G-Rex M 6-well plates were used for rapid expansion, yielding high doses of functional CD8+ T cells.

This study presents a therapeutic strategy combining CIK cells with the anti-CD20 antibody obinutuzumab. CIK cells were successfully expanded from patient PBMCs using G-Rex gas-permeable. The combination showed high cytotoxicity against B-cell malignancies in vitro and in vivo.

This Phase I trial assessed TIL therapy in metastatic NSCLC. Autologous TILs were expanded using a rapid expansion protocol in G-Rex 100 MCS. The treatment demonstrated manageable toxicity and induced durable complete responses in some patients.

This pilot study evaluated BKV-specific T cells (PyVST) for PML treatment. PyVSTs were generated from related donors and expanded in G-Rex tissue culture containers for 14 days. The therapy was safe, with some patients showing survival and viral load reduction.

This study established a method to expand SARS-CoV-2 specific T cells from convalescent donors. Using G-Rex culture vessels, including CS100M, the protocol achieved high yields of central memory T cells within 21 days for potential allogeneic therapy.

This study improved EBV-specific T cell manufacturing using GMP reagents and G-Rex. G-Rex100 yielded higher CD8+ T cell percentages and expansion compared to standard flasks. Detailed cytokine profiling characterized the product phenotype.